Neuroendocrine Tumor Clinical Trials (2026): 533 Recruiting Interventional Studies

Last updated: March 9, 2026

Current Clinical Trial Landscape

Neuroendocrine tumors (NETs) include:

GEP-NETs — gastroenteropancreatic (pancreas, small bowel, stomach)
Carcinoid tumors — lung, GI tract
Pheochromocytoma/paraganglioma

Active research areas in 2026:

PRRT / Lutetium-177 combinations (45 trials)
Somatostatin analogs (39 trials)
Checkpoint inhibitors (176 trials)
mTOR inhibitors (11 trials)

Standard of care: Somatostatin analogs (octreotide, lanreotide) for symptom control. PRRT (Lutathera) for progressive somatostatin receptor-positive tumors. Everolimus or sunitinib for progressive disease.

Recruiting Trials by Treatment Setting

First-Line / Newly Diagnosed

For previously untreated advanced NETs:

Somatostatin analogs: Standard first-line for well-differentiated NETs
- View somatostatin analog trials →
PRRT in first-line:
- NCT06784752 - 177Lu-DOTATATE in Grade 1-2 GEP-NETs

Second-Line / Progressive Disease

After progression on somatostatin analogs:

PRRT:
- NCT05687123 - Lutathera + Sunitinib in pancreatic NETs
- NCT07185672 - PRRT vs PRRT + chemotherapy
Targeted therapy:
- NCT06943755 - Zanzalintinib vs Everolimus

Surgery Combinations

NCT06016855 - Surgical debulking before PRRT

Trials by Treatment Approach

PRRT / Lutetium-177 (45 trials)

Peptide receptor radionuclide therapy targets somatostatin receptors. Lutathera (177Lu-DOTATATE) is approved; trials explore combinations and sequencing. View all →

NCT05687123 - Lutathera + Sunitinib in pancreatic NETs
NCT07185672 - PRRT vs PRRT + chemotherapy (PReCedeNT)
NCT06784752 - 177Lu-DOTATATE in Grade 1-2 GEP-NETs
NCT06016855 - Surgical debulking before PRRT

Somatostatin Analogs (39 trials)

Octreotide and lanreotide control hormone secretion and slow tumor growth. Trials explore higher doses and combinations. View all →

Targeted Therapy (mTOR, TKI)

Everolimus (mTOR inhibitor) and sunitinib (TKI) are approved for progressive NETs. Trials test new agents and combinations.

NCT06943755 - Zanzalintinib vs Everolimus in advanced NETs

View all mTOR/TKI trials →

Immunotherapy (176 trials)

Checkpoint inhibitors show modest activity in NETs; trials explore combinations to improve response. View all →

Trials by NET Subtype

Pancreatic NETs

NCT05687123 - Sunitinib + Lutathera
View all pancreatic NET trials →

GI / Carcinoid Tumors

NCT06321692 - Early cardiac involvement in carcinoid
View all carcinoid trials →

GEP-NETs (General)

NCT07185672 - PRRT +/- chemotherapy
View all GEP-NET trials →

Trial listings from ClinicalTrials.gov. Page summaries generated by AI and may contain errors. Always verify with your healthcare provider.

Find NET Trials Matched to Your Situation

Use ClinTrialFinder's AI-powered matching to find trials based on your specific condition and tumor type.

Find Matching Trials